

ABSTRACT

5       A therapeutic agent for myeloma comprising a  
combined use of a nitrogen mustard anticancer agent and  
anti-IL-6 receptor antibody. Thus, a therapeutic agent  
for myeloma comprising anti-IL-6 receptor antibody for  
use in combination with a nitrogen mustard anticancer  
agent; a therapeutic agent for myeloma comprising a  
nitrogen mustard anticancer agent for use in combination  
10   with anti-IL-6 receptor antibody; and a therapeutic agent  
for myeloma comprising a nitrogen mustard anticancer  
agent and anti-IL-6 receptor antibody.